Erythrocyte membrane composition in patients with primary hypercholesterolemia

被引:10
作者
Vaya, A. [1 ]
Martinez Triguero, M. [1 ]
Reganon, E. [2 ]
Vila, V. [2 ]
Martinez Sales, V. [2 ]
Sola, E. [3 ]
Hernandez Mijares, A. [3 ]
Ricart, A. [4 ]
机构
[1] La Fe Univ Hosp, Dept Clin Pathol, Haemorheol & Thrombosis Unit, Valencia 46009, Spain
[2] La Fe Univ, Res Ctr, Valencia, Spain
[3] Dr Peset Univ Hosp, Valencia, Spain
[4] Univ Politecn Valencia, Dept Appl Linguist, E-46071 Valencia, Spain
关键词
Erythrocyte membrane lipid composition; primary hypercholesterolemia; BLOOD-CELL AGGREGATION; FAMILIAL HYPERCHOLESTEROLEMIA; PRIMARY HYPERLIPOPROTEINEMIA; TYPE-2; HYPERCHOLESTEROLEMIA; PLASMA-LIPIDS; CHOLESTEROL; ATORVASTATIN; MARKER; AGE;
D O I
10.3233/CH-2009-1156
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There are conflicting results regarding the erythrocyte membrane cholesterol and phospholipid content in patients with primary hypercholesterolemia (PHC), due to methodological problems in obtaining haemoglobin-free ghosts. At the same time, the different units used and the fact that the cholesterol and phospholipids are not expressed in relation with integral protein membrane content, produces contradictory results. We have analysed in 33 patients with PHC (12 males, 31 females) aged 43 +/- 12 years and in 33 healthy normolipaemic volunteers (9 males, 24 females) aged 43 +/- 13 years plasma lipids, along with, erythrocyte membrane cholesterol, phospholipids and integral proteins. PHC patients showed increased erythrocyte membrane cholesterol: 0.36 +/- 0.15 mg/mg when compared with controls: 0.29 +/- 0.75 mg/mg; p = 0.018. Phospholipid membrane content, although higher in the cases, did not reach statistical significance (PHC patients: 0.38 +/- 0.15 mg/mg vs. 0.33 +/- 0.72 mg/mg; p = 0.098). The cholesterol/phospholipids ratio (Chol/Ph) was 0.99 +/- 0.22 in PHC patients versus 0.92 +/- 0.28 in controls; p = 0.127. Our results suggest that there is a slight increase in erythrocyte membrane cholesterol in patients with PHC. Given the increasing importance of erythrocyte membrane cholesterol in the stability of the atheroma plaque due its possible contribution to the clinical signs of ischaemic heart disease, it seems relevant to determine this parameter in risk populations. Therefore, a simple and reproducible method needs to be standardised which would enable comparisons between laboratories and facilitate further studies aimed to it as a marker of acute coronary syndromes.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 29 条
[1]  
Aloulou I, 2006, CLIN HEMORHEOL MICRO, V35, P207
[2]   Total erythrocyte membrane cholesterol - An innocent new marker or an active player in acute coronary syndromes? [J].
Arbustini, Eloisa .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (21) :2090-2092
[3]  
Broncel Marlena, 2007, Wiad Lek, V60, P321
[4]  
Broncel Marlena, 2007, Wiad Lek, V60, P4
[5]   BILE SALTS AND CHOLESTEROL IN PATHOGENESIS OF TARGET CELLS IN OBSTRUCTIVE JAUNDICE [J].
COOPER, RA ;
JANDL, JH .
JOURNAL OF CLINICAL INVESTIGATION, 1968, 47 (04) :809-&
[6]   PREPARATION AND CHEMICAL CHARACTERISTICS OF HEMOGLOBIN-FREE GHOSTS OF HUMAN ERYTHROCYTES [J].
DODGE, JT ;
HANAHAN, DJ ;
MITCHELL, C .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1963, 100 (01) :119-&
[7]  
DUWIGHT JF, 1996, CLIN CHIM ACTA, V256, P53
[8]   Intraplaque hemorrhage and progression of coronary atheroma [J].
Kolodgie, FD ;
Gold, HK ;
Burke, AP ;
Fowler, DR ;
Kruth, HS ;
Weber, DK ;
Farb, A ;
Guerrero, LJ ;
Hayase, M ;
Kutys, R ;
Narula, J ;
Finn, AV ;
Virmani, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (24) :2316-2325
[9]   Free cholesterol in antherosclerotic plaques: where does it come from? [J].
Kolodgie, Frank D. ;
Burke, Allen P. ;
Nakazawa, Gaku ;
Cheng, Qi ;
Xu, Xin ;
Virmani, Renu .
CURRENT OPINION IN LIPIDOLOGY, 2007, 18 (05) :500-507
[10]   Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia [J].
Koter, M ;
Franiak, I ;
Broncel, M ;
Chojnowska-Jezierska, J .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2003, 81 (05) :485-492